Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5212
Abstract: Asciminib, a first‐in‐class, allosteric inhibitor of BCR‐ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open‐label… read more here.
Keywords: ascembl study; cml; subgroup analysis; study ... See more keywords
Multiplicity considerations in subgroup analysis.
Sign Up to like & getrecommendations! Published in 2017 at "Statistics in medicine"
DOI: 10.1002/sim.7416
Abstract: This paper deals with the general topic of subgroup analysis in late-stage clinical trials with emphasis on multiplicity considerations. The discussion begins with multiplicity issues arising in the context of exploratory subgroup analysis, including principled… read more here.
Keywords: considerations subgroup; subgroup analysis; analysis; multiplicity considerations ... See more keywords
Subgroup analysis with semiparametric models toward precision medicine.
Sign Up to like & getrecommendations! Published in 2018 at "Statistics in medicine"
DOI: 10.1002/sim.7638
Abstract: In analyzing clinical trials, one important objective is to classify the patients into treatment-favorable and nonfavorable subgroups. Existing parametric methods are not robust, and the commonly used classification rules ignore the fact that the implications… read more here.
Keywords: medicine; medicine subgroup; subgroup analysis; semiparametric models ... See more keywords
Propensity score weighting for causal subgroup analysis
Sign Up to like & getrecommendations! Published in 2021 at "Statistics in Medicine"
DOI: 10.1002/sim.9029
Abstract: A common goal in comparative effectiveness research is to estimate treatment effects on prespecified subpopulations of patients. Though widely used in medical research, causal inference methods for such subgroup analysis (SGA) remain underdeveloped, particularly in… read more here.
Keywords: subgroup; causal; score weighting; subgroup analysis ... See more keywords
Evaluating the impact of digital therapy for male LUTS: insights from the BEST trial subgroup analysis
Sign Up to like & getrecommendations! Published in 2025 at "World Journal of Urology"
DOI: 10.1007/s00345-025-06016-2
Abstract: Men with lower urinary tract symptoms (LUTS) represent a heterogeneous patient population. The BEST trial investigated the effectiveness of a digital health application for male LUTS. This pre-specified subgroup analysis evaluated treatment effects based on… read more here.
Keywords: best trial; male luts; subgroup analysis; trial ... See more keywords
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
Sign Up to like & getrecommendations! Published in 2022 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01271-9
Abstract: Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS… read more here.
Keywords: subgroup analysis; efficacy safety; ftd tpi; placebo ... See more keywords
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-024-02583-3
Abstract: In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8 months) and reduced risk of death by 36% (hazard ratio 0.64, P = 0.005) compared with chemotherapy in metastatic… read more here.
Keywords: metastatic urothelial; erdafitinib; subgroup analysis; japanese subgroup ... See more keywords
Subgroup Analysis of Antibiotic Treatment for Skin Abscesses
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Emergency Medicine"
DOI: 10.1016/j.annemergmed.2017.07.483
Abstract: Study objective Two large randomized trials recently demonstrated efficacy of methicillin‐resistant Staphylococcus aureus (MRSA)–active antibiotics for drained skin abscesses. We determine whether outcome advantages observed in one trial exist across lesion sizes and among subgroups… read more here.
Keywords: treatment; trimethoprim sulfamethoxazole; subgroup analysis; skin abscesses ... See more keywords
Twenty-four-month outcomes of drug-coated balloon in diabetic patients in the BIOLUX P-III registry: a subgroup analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Annals of vascular surgery"
DOI: 10.1016/j.avsg.2021.02.050
Abstract: OBJECTIVES This study aims to assess the use of drug-coated balloon (DCB) in a large patient population under real-world conditions and, specifically, analyse the impact of diabetes mellitus on long term outcomes following DCB utilisation.… read more here.
Keywords: diabetic patients; coated balloon; subgroup analysis; drug coated ... See more keywords
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0554-1
Abstract: GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (CLL). We report the preplanned subgroup analysis of… read more here.
Keywords: lymphocytic leukemia; analysis; previously untreated; subgroup analysis ... See more keywords
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01135-2
Abstract: Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this… read more here.
Keywords: exposed refractory; multiple myeloma; subgroup analysis; analysis ... See more keywords